Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice

被引:292
作者
DiLillo, David J. [1 ]
Hamaguchi, Yasuhito [1 ]
Ueda, Yoshihiro [1 ]
Yang, Kaiyong [1 ]
Uchida, Junji [1 ]
Haas, Karen M. [1 ]
Kelsoe, Garnett [1 ]
Tedder, Thomas F. [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA
关键词
D O I
10.4049/jimmunol.180.1.361
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD20 mAb-mediated B cell depletion is an effective treatment for B cell malignancies and some autoimmune diseases. However, the full effects of B cell depletion on natural, primary, and secondary Ab responses and the maintenance of Ag-specific serum Ig levels are largely unknown. The relationship between memory B cells, long-lived plasma cells, and long-lived Immoral immunity also remains controversial. To address the roles of B cell subsets in the longevity of Immoral responses, mature B cells were depleted in mice using CD20 mAb. Peritoneal B cell depletion reduced natural and Ag-induced IgM responses. Otherwise, CD20(+) B cell depletion prevented Immoral immune responses and class switching and depleted existing and adoptively transferred B cell memory. Nonetheless, B cell depletion did not affect serum Ig levels, Ag-specific Ab titers, or bone marrow Ab-secreting plasma cell numbers. Coblockade of LFA-1 and VLA-4 adhesion molecules temporarily depleted long-lived plasma cells from the bone marrow. CD20(+) B cell depletion plus LFA-1/VLA-4 mAb treatment significantly prolonged Ag-specific plasma cell depletion from the bone marrow, with a significant decrease in Ag-specific serum IgG. Collectively, these results support previous claims that bone marrow plasma cells are intrinsically long-lived. Furthermore, these studies now demonstrate that mature and memory B cells are not required for maintaining bone marrow plasma cell numbers, but are required for repopulation of plasma cell-deficient bone marrow. Thereby, depleting mature and memory B cells does not have a dramatic negative effect on preexisting Ab levels.
引用
收藏
页码:361 / 371
页数:11
相关论文
共 62 条
[1]  
BENNER R, 1981, CLIN EXP IMMUNOL, V46, P1
[2]   Maintenance of serological memory by polyclonal activation of human memory B cells [J].
Bernasconi, NL ;
Traggiai, E ;
Lanzavecchia, A .
SCIENCE, 2002, 298 (5601) :2199-2202
[3]   MEMORY B-CELLS AT SUCCESSIVE STAGES OF DIFFERENTIATION - EXPRESSION OF SURFACE IGD AND CAPACITY FOR SELF RENEWAL [J].
BLACK, SJ ;
TOKUHISA, T ;
HERZENBERG, LA ;
HERZENBERG, LA .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1980, 10 (11) :846-851
[4]   Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis [J].
Cambridge, G ;
Leandro, MJ ;
Edwards, JCW ;
Ehrenstein, MR ;
Salden, M ;
Bodman-Smith, M ;
Webster, ADB .
ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2146-2154
[5]  
Dal Porto JM, 1998, J IMMUNOL, V161, P5373
[6]   Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment [J].
Davis, TA ;
Grillo-López, AJ ;
White, CA ;
McLaughlin, P ;
Czuczman, MS ;
Link, BK ;
Maloney, DG ;
Weaver, RL ;
Rosenberg, J ;
Levy, R .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3135-3143
[7]   Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis - Evidence for a pathogenetic role of B cells [J].
De Vita, S ;
Zaja, F ;
Sacco, S ;
De Candia, A ;
Fanin, R ;
Ferraccioli, G .
ARTHRITIS AND RHEUMATISM, 2002, 46 (08) :2029-2033
[8]   Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes [J].
Edwards, JCW ;
Cambridge, G .
RHEUMATOLOGY, 2001, 40 (02) :205-211
[9]   ABNORMAL B-LYMPHOCYTE DEVELOPMENT, ACTIVATION, AND DIFFERENTIATION IN MICE THAT LACK OR OVEREXPRESS THE CD19 SIGNAL-TRANSDUCTION MOLECULE [J].
ENGEL, P ;
ZHOU, LJ ;
ORD, DC ;
SATO, S ;
KOLLER, B ;
TEDDER, TF .
IMMUNITY, 1995, 3 (01) :39-50
[10]   Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab) [J].
Gonzalez-Stawinski, GV ;
Yu, PB ;
Love, SD ;
Parker, W ;
Davis, RD .
CLINICAL IMMUNOLOGY, 2001, 98 (02) :175-179